ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

2016 American Transplant Congress

June 11-15, 2016 in Boston, MA

View by Title View Sessions
View by Date
Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z
  • c-Kit+ Cells Are Kidney-Specific Progenitor/Stem Cells with Regenerative Potential.

    S. Abreu Gomes,1 G. Goss,2 B. Goldstein,2 B. Seidler,3 D. Saur,3 J. Hare,2 E. Bevilaqua Rangel.1

  • C1-Inhibitor Abrogated Ischemia/Reperfusion (I/R) Induced Inflammaging by Inhibiting Senescence-Associated Secretory Phenotype (SASP) in Tubular Epithelial Cells (TEC).

    G. Castellano,1 R. Franzin,1 A. Stasi,1 C. Divella,1 M. Gigante,1 S. Simone,1 A. Intini,1 A. Picerno,1 P. Pontrelli,1 A. Crovace,1 M. Battaglia,1 B. Oortwijn,2 E. Amersfoort,2 G. Grandaliano,3 L. Gesualdo.1

  • C1-Inhibitor in Acute Antibody-Mediated Rejection Non-Responsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.

    C. Lefaucheur,1 D. Viglietti,1 C. Gosset,1 A. Loupy,2 A. Zeevi,3 D. Glotz.1

  • C1q Assays Are Not Associated with Clinical or Serologic Endpoints.

    A. Gilbert,1 M. Zaheer,1 O. Timofeeva,2 M. Awwad,2 D. Li,2 S. Rosen-Bronson,2 B. Javaid,1 M. Grafals,1 J. Verbesey,1 P. Abrams,1 M. Cooper.1

  • C1q Donor Specific Antibody Associates with Post Transplant Biopsy Findings in Highly Sensitized Kidney Transplant Recipients.

    S. Kuppachi,1 D. Holanda,2 S. Gallegos,3 E. Field.3,4

  • C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains.

    C. Blosser,1 Y. Zhang,2 T. Dhawale,3 C. Johnson,1 P. Hendrie,3 R. Smith.2

  • C5a Induces CSF1-Dependent Regulatory Macrophage (Mreg) Development Required for Murine Allograft Tolerance.

    I. Llaudo, P. Conde, J. Ochando, P. Heeger.

  • Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.

    A. Aliabadi,1 J. Goekler,1 O. Salameh,1 T. Haberl,1 B. Steinlechner,2 P. Opfermann,2 A. Kaider,1 K. Uyanik-Uenal,1 G. Laufer,1 A. Zuckermann.1

  • Calcineurin Inhibitor (CNI) Nephrotoxicity Is Mediated by Defective Amp-Activated Protein Kinase (AMPK) Activation.

    A. Zmijewska, J. Chen, J. Zmijewski, R. Mannon.

  • Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epitheilal to Mesenquimal Transition.

    V. Tubita,1 J. Segui-Barber,4 M.-J. Ramírez-Bajo,1 D. Moya-Rull,1 P. Piselli,3 D. Verdirosi,3 F. Oppenheimer,1,2,5 D. Serraino,6 H. Del Portillo,4,7 F. Diekmann,1,2,5 J. Campistol,1,2,5 I. Revuelta.1,2,5

  • Can OPTN/UNOS Policies Be Effectively Transferred to Another Country's Healthcare System? Russian Case.

    B. Yaremin,1 A. Mironov,4 A. Kolsanov,2 A. Navasardyan,1 R. Akhmetshin,3 A. Starostina.2

  • Can Qrisk Be Useful to Predict Future Cardiovascular Co-Morbidites and Type II Diabetes in Living Kidney Donors Prior to Donation?

    S. Bhutani, R. Chinnadurai, G. Bernal-Blanco, B. Patel, A. Summers, D. Van Dellen, M. Morton, P. Michael.

  • Can We Predict New-Onset Diabetes After Transplantation Previously?

    R. Imamura,1 K. Tsutahara,2 S. Nakazawa,1 Y. Kakuta,1 T. Abe,1 T. Takao,2 N. Ichimaru,3 S. Yamaguchi,2 S. Takahara,3 N. Nonomura.1

  • Cardiovascular Prognosis and Adverse Cardiac Events After Orthotopic Liver Transplantation.

    L. Potena, V. Manfredini, P. Prestinenzi, R. Alabrese, V. Bertuzzo, L. Borgese, M. Masetti, C. Morelli, F. Grigioni, A. Pinna.

  • Caval Replacement versus Piggyback Liver Transplantation: The Toronto Experience.

    A. Barbas, M. Dib, N. Goldaracena, M. Marquez, G. Sapisochin, D. Al-Adra, S. McCluskey, I. McGilvray.

  • CD4 T Cell Mediated Help Is Required for Intra-Allograft Proliferation of Endogenous Memory CD8 T Cells and Their Ability to Mediate Rejection of Cardiac Allografts Subjected to Prolonged Ischemia.

    H. Tsuda, T. Tanaka, C. Su, A. Valujskikh, R. Fairchild.

  • CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.

    C. Cosentino, J. Kaiser, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.

  • CD57+ CD4 T Cells Persist in the Periphery Following Kidney Transplantation.

    J. Espinosa,1,2 L. Stempora,1 R. Townsend,3 A. Kirk.1

  • CD8+TCR– Facilitating Cells in Mobilized Peripheral Blood Mononuclear Cells Are Enriched with IL-10 Producing B Cells.

    Y. Wen, E. Yolcu, Y. Huang, L. Kahn, S. Ildstad.

  • CD9+ Regulatory B Lymphocytes Control Chronic Lung Inflammation by Inducing Effector T Cell Apoptosis.

    C. Brosseau,1,2 M. Durand,1 F. Braza,1 E. Durand,2 J. Loy,2 P. Lacoste,2 P. Royer,2 M.-A. Cheminant,2 A. Magnan,2 S. Brouard.1

  • Center and Surgeons' Experience Improves Outcome in Adult-to-Adult Living Donor Liver Transplantation: Validation of the Report of the A2ALL Consortium.

    S. Nagai, A. Yoshida, M. Rizzari, K. Collins, D. Kim, M. Abouljoud.

  • Center Level Analysis of Changes in Living Donor Transplant Rates in the United States.

    D. Keith, A. Nishio Lucar, G. Vranic.

  • Center Volume Is Associated with Outcome Following Pancreas Transplantation within the Eurotransplant Region.

    W. Kopp,1,2 M. van Meel,2 H. Putter,3 U. Samuel,2 H. Arbogast,4 W. Schareck,5 J. Ringers,1 A. Braat.1

  • Center-Level Variation in Association Between Early Hospital Readmission and Survival Following Kidney Transplantation.

    S. Cramm, E. King, D. Segev.

  • Changes in Fatigue After Kidney Transplantation.

    H. Ying, I. Olorundare, N. Dagher, B. Lonze, R. Montgomery, M. McAdams-Demarco, D. Segev.

  • Characteristics and Outcome of Patients Placed on Extracorporeal Membrane Oxygenation as Bridge to Lung Transplantation.

    E. Batchelor, J. Bland, D. Douglass, J. Mullins, M. Mohanka, S. Bollineni, V. Kaza, M. Wait, F. Torres, A. Banga.

  • Characteristics and Outcomes of Vancomycin Resistant Enterococcus Bacteremia After Liver Transplant.

    R. Odrobina,1 C. Kovacs,1 R. Butler,2 C. Koval.1

  • Characteristics Independently Associated with Kidney Candidates Having CPRA of 99-100%.

    A. Kucheryavaya, D. Klassen, D. Stewart.

  • Characteristics of Compatible Pair Participants in Living Donor Kidney Transplant Exchanges.

    F. Weng, T. Grogan, A. Patel, S. Mulgaonkar, M. Morgievich.

  • Characteristics of Human Rhinovirus (HRV) Infections in Transplant Recipients.

    H. Crossman,1 M. Barron,1 M. Levi.1

  • Characterization of Human Islet Transplant Specific Exosomes in a Xenoislet Transplantation Model.

    P. Vallabhajosyula, L. Korutla, M. Yu, S. Rostami, C.-X. Yuan, C. Liu, V. Korutla, S. Reddy, A. Habertheuer, A. Naji.

  • Characterization of Resistant Cytomegalovirus in Lung Transplant Recipients in the Modern Era.

    S. Hammad, L. Shah, M. Restivo, H. Robbins, J. Scheffert.

  • Characterization of T Regulatory Type 1 (Tr1) Cells in Naïve and Transplanted Non-Human Primates.

    R. Yu, M. Tonsho, P. Spencer, S. Bernard-Stoecklin, G. Benichou, J. Madsen.

  • Characterization of Vascular Lesions in Living Donor Renal Transplant Implant Biopsies.

    F. Tinney Jr,1 L. Yessayan,2 M. Abouljoud,3 A. Patel.3

  • Chemokine Receptor CXCR4 Antagonist, a Novel Pathway to Prevent Chronic Allograft Nephropathy.

    Y. Xu, Q. Zhang, X. Hu.

  • Chemoprevention of Cutaneous Squamous Cell Carcinoma in Renal Transplant Recipients: A Case-Controlled Analysis.

    R. Anand, R. Hung, S. Frame, K. Bramham, M. Wain, A. Cronin.

  • Children Listed as Status 1B for Liver Transplantation Are Disenfranchised by MARS Therapy.

    A. Bakshi,1 M. Kueht,1 A. Rana,1,2 A. Akcan Arikan,3 J. Goss.1,2

  • Chimeric Cell Transplantation for Treatment of Duchenne Muscular Dystrophy: A Preliminary Report.

    E. Szilagyi, E. Bryndza Tfaily, J. Cwykiel, M. Siemionow.

  • Cholangioscopy in Liver Transplant Recipients.

    U. Agbim,1 E. Verna,1 R. Brown, Jr,2 A. Sethi.1

  • Chronic High Epstein-Barr Viral Load Carriage in Pediatric Kidney Transplant Recipients.

    M. Yamada,1 P. Fadaker,1 C. Nguyen,1 A. Ganoza,2 A. Humar,2 M. Michaels,1,2 M. Green.1,2

  • Chronic Infection by Hepatitis C Virus and the Development of Transplant Glomerulopathy.

    D. Regidor,1 S. Alexandru,5 M. Martínez,3 N. Polanco,4 E. González,4 A. Serrano,2 J. Morales.4

  • Cinacalcet Versus Pre-Transplant Parathyroidectomy in Renal Transplant Recipients: Single Centre Experience.

    G. Lucisano,1 R. Charif,1 K. Koutroutsos,1 D. Taube,1 F. Palazzo,2 M. Loucaidou.1

  • Circulating Angiotensin II Receptor: Possible Marker for Antibody Mediated Tissue Injury?

    P. Kimball, F. McDougan, G. Gupta.

  • Circulating Immune Complexes of IgA Bound to Beta 2 Glycoprotein I Is a Predictive Marker for Graft Loss in Patients Positive for IgA aB2GPI.

    J. Morales, M. Serrano, J. Martínez-Flores, D. Perez, M. Sevilla, O. Cabrera, A. Serrano.

  • Circulating miR-215, miR-let-7c miR-154, miR-193a, NR_036506.1 and NR_027669.1 as Biomarkers Predict Fungal Infection in Post-Transplanted Recipients.

    A. Yang, Z. Guo, W. Ju, C. Zhang, Z. Li, X. Yuan, Q. Zhao, H. Ye, Y. Liao, X. Zhu, X. He.

  • Circulating Soluble-Klotho Levels Modestly Increase After Renal Transplantation.

    S.-J. Tan,1 A. Crosthwaite,2 D. Langsford,3 V. Obeysekere,4 F. Ierino,2,5 M. Roberts,5,6 S. Holt,1 T. Hewitson,1 K. Dwyer,3,5,7 N. Toussaint.1

  • Citrate-Based Thermoresponsive Hydrogel as a Versatile Platform for Extrahepatic Islet Transplantation.

    Y. Zhu,1 X. Zhang,2 A. Guillermo,1 X. Luo.2

  • Clinical Analysis of Patients with Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation.

    D. Kim, G. Na, T. Hong, Y. You.

  • Clinical and Immunologic Assessments of Immune Responses in a Liver Transplant Patient with CD40L Deficiency and Hyper IgM Syndrome.

    M. Tseng,1 S. Ge,1 R. Roberts,2 C. Kuo,2 J. Choi,1 N. Nissen,1 M. Chu,1 I. Kim,1 B. Shin,1 M. Toyoda,1 S. Jordan.1

  • Clinical and Subclinical Cardiac Events After Kidney Transplantation (KTX).

    F. Cosio,1 H. Amer,1 M. Keddis,2 A. Jaffe.3

  • Clinical Correlation Between Pairs of Kidneys Transplanted from the Same Donor.

    A. Baheerathan, H. Beckwith, A. McLean, D. Taube, M. Willicombe.

  • Clinical Factors That Determine the Appropriateness of Early Steroid Withdrawal.

    S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, D. Segev.

  • Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.

    S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, F. Al Ammary, D. Segev.

  • Clinical Impact of Pre-Transplant Serum 25-Hydroxyvitamin D Levels on the Post-Transplant Immunologic and Non-Immunologic Outcomes in Kidney Transplant Recipients.

    T. Ban,1,2 J. Kim,1,2 Y. Lee,1 B. Choi,1,2 C. Park,1,2 C. Yang,1,2 Y.-S. Kim,1,2 B. Chung.1,2

  • Clinical Impact of the Verigene® Blood Culture System on Rapid Diagnosis and Antibiotic Optimization in Bacteremic Solid Organ Transplant (SOT) Recipients.

    N. Law,1 G. Malat,3,4 D. Lee,1 A. Doyle,2 C. Emery,1,5 K. Kyle,5 K. Ranganna,2 M. Harhay,2 T. Bias.1,4

  • Clinical Measures to Reduce Early Urinary Tract Infections Following Kidney Transplantation: A Single Center Experience.

    B. Chopra, T. Ko, C. Webster, J. Sheyman, A. Arumgarajah, V. Katragadda, R. Marcus, K. Sureshkumar.

  • Clinical Outcome in Pure T-Cell Mediated Acute Rejection of the Kidney with No Donor Specific Antibody or C4d Staining.

    P. Randhawa,1 G. Huang,2 S. Randhawa,1 G. Zeng,1 X. Zhao.3

  • Clinical Outcome of Elderly Living Kidney Donors: A Single-Center Study in Japan.

    J. Hasegawa, K. Unagami, M. Okumi, K. Omoto, M. Inui, H. Ishida, K. Tanabe.

  • Clinical Outcome on Kidney Retransplantation in Comparison with First Kidney Transplantation in Korea – Nationwide Cohort Study.

    J. Kim,1,2 T. Ban,1,2 B. Jung,1,2 B. Choi,1,2 C. Park,1,2 C. Yang,1,2 Y.-S. Kim.1,2

  • Clinical Outcomes of Kidney Allograft Recipients with Apolipoprotein L1 (APOL1) Risk Alleles from Living Kidney Donors.

    C. Dorr,1,2,3 A. Hart,1,2,3 D. Schladt,1 A. Muthusamy,1 R. Mannon,4 W. Oetting,2 A. Matas,2 P. Jacobson,2 A. Israni.1,2,3

  • Clinical Outcomes of Simplified Once-Daily Immunosuppressive Regimen for Kidney Recipients.

    C.-K. Oh,1 S.-J. Kim,2 K. Huh,3 S. Kim,4 H. Cho,5 S. Lee.6

  • Clinical Prediction Tool to Guide Referral of Elderly Dialysis Patients for Kidney Transplant Evaluation.

    L.-X. Chen,1 M. Josephson,1 N. Stankus,1 K. Campbell,1 D. Hedeker,2 M. Saunders.1

  • Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.

    A. Alghamdi, A. Humar, Y. Natori, S. Husain, L. Singer, E. Renner, C. Rotstein, D. Kumar.

  • Clinical Rejection-Risk Assessment with Allospecific CD154+T-Cytotoxic Memory Cells (CD154+TcM) After Pediatric Liver or Intestine Transplantation (LTx, ITx).

    K. Soltys, G. Bond, G. Mazariegos, L. O'Toole, C. Trautz, L. Remaley, A. Zeevi, C. Ashokkumar, R. Sindhi.

  • Clinical Risk Factors for the Recurrence of Clostridium difficile Infection (CDI) in Solid Organ Transplant Recipients (SOTR).

    Y. Natori, M. Shiotsuka, L. Oen, E. Renner, L. Singer, J. Kim, H. Ross, D. Kumar, C. Rotstein, A. Humar, S. Husain.

  • Clinical Significance of C3d Binding Donor Specific Anti-HLA Antibodies (DSA) Detected by Single Antigen Beads (SAB) After Kidney Transplantation.

    R. Pelletier,1 I. Balazs,2 P. Adams,3 P. Steller,3 N. DiPaola,4 L. Rankin,3 A. Diez,5 M. Henry.1

  • Clinical Significance of Isolated v1 Arteritis in Renal Transplantation.

    D. Mikhail,1,3 J. Wei,3 D. Kleinsteuber,2 M. Gabril,2,3 A. Sener,1,3 M. Moussa,2,3 P. Luke.1,3

  • Clinical Significance of Mycophenolic Acid Therapeutic Drug Monitoring in Kidney Transplant Recipients.

    C.-D. Kim, J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim.

  • Clinical Significance of Non-HLA Antibodies in the Development of Microcirculation Inflammation in Allograft Tissue After Kidney Transplantation.

    J. Min,1,3 H. Lee,2,3 B. Chung,1,3 E.-J. Oh,2,3 C. Yang.1,3

  • Clinical Significance of Solitary Pulmonary Nodules in Liver Transplant Recipients with Hepatocellular Carcinoma.

    O. Serrano,1 A. Bangdiwala,2 D. Vock,2 V. Kirchner,1 K. Yadav,1 A. Pugalendhi,1 E. Minja,1 T. Dunn,1 E. Finger,1 A. Matas,1 R. Kandaswamy,1 W. Payne,1 T. Pruett,1 S. Chinnakotla.1

  • Clinical Usefulness of mRECIST Response to Chemoembolization for Recurrence Prediction of Hepatocellular Carcinoma in Living Donor Liver Transplantation.

    C. Cho, K. Kim, S. Kim, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, N. Lee.

  • Clinical, Histologic and Charge Endpoints When Populations with Hepatitis C Recurrence Are Treated with Direct-Acting Antiviral or Interferon Based Therapies.

    S. Olson, A. McCann, S. Kumer, T. Schmitt, B. Floyd, R. Taylor, R. Gilroy.

  • Clonal Expansion of Donor-Specific Tregs Following Combined Kidney and Bone Marrow Transplantation.

    T. Savage,1 S. Dewolf,1 A. Obradovic,1 S. Lau,1 J. Zuber,1 L. Turka,2,3 Y. Shen,1 M. Sykes.1

  • CMV Immune Monitoring with a CMV ELISPOT Test in Kidney Transplant Patients.

    S. Ball, A. Small, C. Waite.

  • CMV Monitoring Reduces Risk of Clinical Complications in Kidney Transplant Recipients.

    A. Gilbert, M. Cooper, J. Verbesey, R. Ghasemian, P. Abrams, J. Moore, M. Grafals, J. Chahine, S. Punnett, E. Hall, I. Anzak, B. Javaid.

  • CMV-Accelerated Cardiac Allograft Rejection Is Associated with Dysregulation of Sphingolipid Metabolomics.

    J. Burg,1 T. Andoh,2 N. Haese,2 C. Kreklywich,2 K. Watters,3 T. Metz,3 S. Orloff,1 D. Streblow.2

  • CoCl2 Induced ER Stress Protein Mediated Cytotoxicity in FK506 Treated Hepatoma HepG2 Cells.

    S. Choi, S. Chung.

  • Cognitive Impairment in Kidney Transplant Recipients.

    A. Gupta,1 D. Johnson,1 G. Chen,1 D. Subramaniam,1 T. Polshak,1 T. Thomas,1 T. Schmitt,1 D. Ladner,2 A. Yu,1 J. Burns.1

  • Cold Ischemia Induced Outcomes in Kidney Transplantation: A Meta-Analysis.

    D. Bennett, M. Mustafa, M. Chiles, W. Skillen, S. Mohan.

  • Cold Storage Stabilization of Gap Junctions Reduces Post Transplant Ischemia Reperfusion Injury.

    R. Finnegan,1 P. Zhu,1 S. Stephenson,1 K. Patel,2 S. Nadig,1,2,3 C. Atkinson.1,2,3

  • Colonization and Risk of Bacteremia by Multi-Drug Resistant Organisms in Intestinal Transplant Recipients.

    J. Simkins,1 J. Camargo,1 M. Morris,1 R. Vianna,2 T. Beduschi,2 L. Abbo.1

  • Combination of Delayed Kidney Transplant (KT) and Better Quality Kidneys Offers Excellent Patient Survival in Combined Liver-Kidney Transplantation (CLKT).

    B. Ekser, R. Mangus, J. Fridell, C. Kubal, D. Bayt, S. Nagaraju, P. Mihaylov, J. Powelson, W. Goggins, A. Tector.

  • Combination of Veto Cell Transfer and iNKT Cell Therapy Establishes Complete Hematopoietic Chimerism in Non-Myeloablative BMT Recipients.

    R. Ishii,1 T. Hirai,1 Y. Ishii,2 K. Tanabe.1

  • Combined CD122 and Costimulation Blockade Prolongs Allograft Survival by Controlling Expansion and Effector Function of Memory CD8 T Cells.

    D. Mathews,1 Y. Dong,1 L. Higginbotham,1 S. Kim,1 C. Breeden,1 J. Tso,2 A. Adams.1

  • Combined Liver-Kidney Transplantation for Polycystic Liver and Kidney Disease: Analysis from the UNOS Dataset.

    C. Coquillard, J. Berger, M. Daily, X. Mei, F. Marti, M. Shah, R. Gedaly.

  • Combined Liver-Kidney Transplantation in Children: Long-Term Follow-Up in 27 Children.

    M. Kemper,1 B. Nashan,2 L. Fischer,2 F. Brinkert.1

  • Common Iliac Artery Stenosis: An Often Overlooked Cause of Graft Dysfunction.

    E. Christie, P. Campbell, K. Wen.

  • Common Molecular Features of Human Kidney Transplant Rejection Reflect Mechanistic Sharing Between T Cell-Mediated and Antibody-Mediated Rejection.

    J. Venner,1,2 P. Halloran.2

  • Comparative Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma (HCC-CCA) Undergoing Liver Transplantation: A Single Center Matched Cohort Analysis.

    K. Lunsford, M. Harlander-Locke, J. Gornbein, A. Zarrinpar, F. Kaldas, H. Yersiz, D. Farmer, R. Busuttil, V. Agopian.

  • Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.

    C. Santos, M. Saeed, D. Brennan, M. Olsen.

  • Comparing Renal Function After Liver Transplantation: Modified Piggyback versus Conventional Techniques without Venovenous Bypass.

    J. Lee, J. Lee, S. Song, J. Lee, S.-K. Kwon, D. Han, M. Ju, G. Choi, J. Choi, M. Kim, S. Kim, D. Joo.

  • Comparison of Actual versus Goal Tacrolimus Levels Post Cardiothoracic Transplant.

    E. Milas, I. Feurer, C. Truscott, J. Gray, N. Wilson, S. Bala, T. Dreher, M. Wigger, M. Steele, A. Shah, E. Lambright, D. Hanto.

  • Comparison of C4d Deposition in Renal Biopsies with Luminex-Based C3d Single Antigen Bead (SAB) Detection.

    R. Pelletier,1 I. Balazs,2 P. Adams,3 P. Steller,3 N. DiPaola,4 L. Rankin,3 A. Diez,5 M. Henry.1

  • Comparison of Clinical Outcomes in Lung Transplant Patients with and without Preoperative Pulmonary Hypertension.

    A. Kalya, M. Boga, S. Dasyam, R. Walia, M. Smith, R. Bremner, A. Omar, V. Patel, E. Kuo, J. Huang, S. Hashimi.

  • Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.

    X. Wen,1 M. Casey,1 A. Santos,1 A. Hartzema,2 K. Womer.1

  • Comparison of De Novo Donor Specific Antibody Formation for Kidney Transplant Recipients Induced with Thymoglobulin or Basiliximab.

    A. Gong, K. Lee, S. Patel, M. Brande, R. Dhawan, C. Parke, M. Smogorzewski, L. Aguirre, B. Duong, S. Alexopolus, Y. Qazi.

  • Comparison of Early Engraftment Immunobiology of Xenoislets and Alloislets in a Dual Transplant Model.

    K. Samy,1 B. Martin,2 M. Song,1 B. Collins,1 E. Gall,1 J. Cano,2 A. Farris,2 F. Leopardi,1 A. Kirk.1,2

  • Comparison of EDTA, DTT and Dilutions to Abrogate the Prozone Effect in Luminex-Based HLA Antibody Assays.

    M. Pando, S. Franklin, L. Nelson, Y. Desmarteau, A. Jaramillo.

  • Comparison of Efficacy and Safety of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus.

    P. Gatault,1 N. Kamar,2 M. Buchler,1 C. Colosio,3 D. Bertrand,4 A. Durrbach,5 L. Albano,6 J. Rivalan,7 M. Essig,8 Y. Le Meur,9 N. Bouvier,10 B. Charpentier,5 E. Thervet,11 L. Rostaing,2 Y. Lebranchu.1

  • Comparison of Efficacy of Different Regimens for Treating Recurrent IgA Nephropathy After Kidney Transplantation.

    G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang, J. Fei, S. Deng, J. Li, G. Huang, Q. Fu.

  • Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients.

    Y. Watarai,1 M. Okada,1 K. Futamura,1 T. Nagai,1 T. Yamamoto,1 M. Tsujita,1 T. Hiramitsu,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

  • Comparison of Once-Daily and Twice-Daily Low-Dose Tacrolimus in Living Related Kidney Transplantation – Prospective Trial of Once-Daily vs. Twice-Daily Tac – 5 Years Second Report.

    T. Tsuchiya, H. Ishida, T. Nozaki, H. Shirakawa, T. Shimizu, K. Omoto, M. Okumi, K. Tanabe.

  • Comparison of Outcomes from Patients with Completion versus Total Pancreatectomy with Islet Autotransplantation: A Single-Institution Experience with 120 Consecutive Cases.

    G. Yoshimatsu,1 M. Takita,1 R. Shahbazov,2 M. Lawrence,1 B. Naziruddin,3 P. Kim,3 M. Levy,4 N. Onaca.3

  • Comparison of Outcomes of Kidney Transplantation from DBD, DCD or DBCD Donors: A Single Center Experience from China.

    G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang.

  • Comparison of Pharmacokinetic and Clinical Outcomes of Tacrolimus Hexal® with Prograf® Based Regimen in De Novo Kidney Transplant Recipients: Results from the Randomized, SparTacus Study.

    W. Arns,1 A. Huppertz,1 T. Rath,1 S. Ziefle,1 L. Rump,1 A. Hansen,1 D. Baeumer,2 K. Budde,1 L. Lehner,1 T. Klein,1 P. Schenker.1

  • Comparison of Renal Outcomes Between ABO-Incompatible and Kidney Paired Donation Transplantation In Living Donors.

    N. Hashemi, M. Tavakol, B. Lee.

  • Comparison of Surgical Correction Techniques for Post-Kidney Transplantation Vesicoureteral Reflux.

    V. Turunç,1 A. Eroğlu,2 B. Tabandeh,1 H. Dheir,2 E. Basok,3 A. Erol.3

  • Comparison of Three Approaches for Laparoscopic Donor Nephrectomy: Transvaginal, Transumbilical Single Site and Retroperitoneal.

    M. Miura, H. Higashiyama.

  • Comparison of Transplant Outcomes for Low-Dose and Standard-Dose Tacrolimus in Kidney Transplant Recipients.

    J.-H. Cho, K. Kim, M. Kim, W. Do, Y. Yang, T. Yim, I. Hwang, J.-H. Lee, E. Kwon, H.-Y. Jung, J.-Y. Choi, S.-H. Park, Y.-L. Kim, C.-D. Kim.

  • Compensating Live Kidney Donors: The Views of United States Voters.

    J. Fisher,1 T. Peters,2 R. Gish,3 R. Howard.4

  • Complement Receptor C5aR2 Deletion in Kidney Transplantation in Mice Attenuates Renal Damage.

    A. Thorenz,1 R. Chen,1 K. Hueper,2 B. Hensen,2 C. Klemann,3 M. Meier,4 A. Klos,5 F. Gueler.1

  • Complement-Binding Donor-Specific Anti-HLA Antibodies Are Associated with Severe Kidney Allograft Arteriosclerosis.

    A. Loupy,1 D. Viglietti,2 J. Duong Van Huyen,1 D. Glotz,2 C. Legendre,1 A. Zeevi,3 C. Lefaucheur.2

  • Complex Constellation of HLA Antibodies Contributes to Decreasing Trend of Transplant Rate in Candidates with 100% CPRA.

    R. Rajalingam, D. Hyon Gae, D. Kopchaliiska, O. Buenaventura, K. Cunniffe, G. Da Gente, J. Roberts.

  • Complexity of Hylinosis in Renal Transplant Biopsies: Donor Age, Glomerular Disease, and Time.

    G. Einecke,1 J. Reeve,2 P. Halloran.2,3

  • Complications of Dual Antiplatelet Therapy Among Recipients of Kidney Transplants.

    F. Weng, A. Athavale, K. Hussain, K. Tibaldi, G. Rogal.

  • Composite Score to Define the Risk of Allograft Loss After Standard-of-Care Treatment of Antibody-Mediated Rejection in Kidney Transplantation.

    D. Viglietti,1 A. Loupy,2 J. Duong Van Huyen,2 J. Verine,1 A. Zeevi,3 C. Legendre,2 D. Glotz,1 C. Lefaucheur.1

  • Computed Tomography Measures of Nutrition Deficits in Patients with Intestine Failure.

    J. Davis, W. Bush, C. Kubal, R. Mangus.

  • Concomitant Proton Pump Inhibitor and Mycophenolate Mofetil Use in Renal Transplant Recipients.

    K. Patel,1 B. Stephany,2 J. Barnes,1 S. Bauer,1 M. Spinner.1

  • Concordance Between Pancreatic Rejection and Kidney Rejection and Kidney Survival in Simultaneous Pancreas Kidney Transplantation.

    I. Moinuddin, T. Taber, M. Yaqub, D. Mishler, O. Adebiyi, J. Chen, M. Goble, J. Powelson, J. Fridell, A. Sharfuddin.

  • Conditional Deletion of mTOR in Myeloid Cells Inhibits Chronic Allograft Rejection – A Novel Role for Macrophages in Transplant Vasculopathy.

    Y. Zhao, W. Chen, P. Lan, X. Xiao, W. Liu, M. Kloc, Y. Liu, R. Ghobrial, O. Gaber, X. Li.

  • Conditional Long Term Intestine Patient and Graft Survival Is Improving Under rATG Immunosuppression in Pediatric Intestine Transplantation.

    N. Celik,1 F. Vyas,1 G. Bond,1 K. Soltys,1 J. Rudolph,2 R. Sindhi,1 G. Mazariegos.1

  • Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.

    S. Patel, R. Knight, S. Kuten, J. Nolte, A. Gaber.

  • Continuous Glucose Monitoring in the First 6 Weeks After Transplantation in Pancreas Transplant Recipients.

    K. Bonner,1 V. Dadlani,2 P. Thapa,2 M. Stegall,1 Y. Kudva.2

  • Contrasting Effects of Tacrolimus and Everolimus on Regulatory T Cell Activation and Mixed Hematopoietic Chimerism Induced by Natural Killer T Cell Stimulation.

    S. Miyairi,1,2 T. Hirai,1 R. IShii,1 M. Okumi,1 Y. Ishii,3 S. Nunoda,2 K. Yamazaki,2 K. Tanabe.1

  • Contributions of Naive vs. Endogenous and Induced Alloreactive Memory T Cells in Mixed Lymphocyte Reactions.

    J. Lee, G. Benichou.

  • Controlled Cardiac Death Donor Program for Kidney Transplantation – Spanish Multicenter Experience with Two Years of Follow-Up.

    J. Portoles,1 M. Perez-Saez,2 D. Hernandez-Marrero,2 O. Lafuente,1 F. Diekmann,2 N. Maruri Kareaga,2 M. Rodriguez-Ferrero,2 F. Llamas,2 M. Mazuecos,2 J. Juega,2 E. Melilli,2 A. Rodriguez-Benot,2 A. Alonso,2 J. Pascual.2

  • Controlled Oxygenated Rewarming and Subnormothermic Machine Perfusion of Steatotic Livers: First Clinical Results.

    D. Hoyer,1 A. Gallinat,1 J. Treckmann,1 T. Benkoe,1 S. Swoboda,1 U. Rauen,2 A. Paul,1 T. Minor.1

  • Conversion from Tacrolimus (TAC) to Sirolimus (SLR)-Based Immunosuppression in Pediatric Patients Who Underwent Liver Transplantation for Unresectable Hepatoblastoma – 2 Year Follow-Up.

    R. Hendrickson,1 W. Andrews,1 M. Davis,1 R. Cisneros,1 R. Fischer,2 J. Daniel.2

  • Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease.

    A. Sharfuddin, J. Chen, M. Yaqub, T. Taber, J. Powelson, D. Mishler, M. Goble, J. Fridell, O. Adebiyi, M. Mujtaba.

  • Conversion to Belatacept as Rescue Therapy in Kidney Transplant Recipients with Severe Graft Dysfunction.

    F. Oldhafer,1 M. Hiss,2 A. Schwarz,2 H. Haller,2 G. Einecke.2

  • Conversion to Once-Daily Tacrolimus in Stable Pediatric Liver Transplantation Recipients.

    N. Lee, S. Lee, C.-W. Cho, J. Lee, J. Lee, J. Kim, G.-S. Choi, C. Kwon, J.-W. Joh, S.-K. Lee.

  • Coping with Patient Death on Pediatric Liver Transplant Teams.

    S. Duncan,1 R. Arnon,2 C. Dipietroantonio,1 C. Knight,1 J. Chu,2 R. Annunziato.1

  • Correlation of the Shear Wave Elastography with Renal Function in Kidney Transplant Recipients: A Proof of Concept Study.

    J. Dosal-Bañuelos, A. Flores-Mendoza, L. Morales-Buenrostro, M. Díaz-Zamudio.

  • Cost-Effectiveness of Machine Perfusion Use After Long Cold Ischemic Time in a Kidney Transplantation Program.

    A. Matos, D. Malheiros, S. Morgado, L. Requiao-Moura, M. Borrelli, M. Nogueira, M. Durao, E. Tonato, A. Pacheco-Silva.

  • Costimulation Blockade by Anti CD40 Antibody Prevents Humoral and Cellular Rejection of Heterotopic Pig Cardiac Xenograft.

    A. Singh,1 J. Chan,1 P. Corcoran,1 B. Lewis,2 M. Thomas,2 D. Ayares,3 K. Horvath,1 M. Mohiuddin.1

  • Creation of a Small Animal Model of Ex-Vivo Normothermic Perfusion (EVNP) for Treatment of Kidney Ischemia-Reperfusion (I/R) Injury.

    Y. Smolin, I. Palma, C. Pivetti, S. Kabagambe, J. Woloszyn, Y. Chen, T. Boyer, I. Palma, J. Sageshima, C. Santhanakrishnan, R. Perez.

  • Crisis on the Waiting List for Children Listed in Low Volume Solid Organ Transplant Centers.

    A. Rana, E. Brewer, W. Winkelmayer, C. O'mahony, J. Goss.

  • Criteria for the Diagnosis of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx).

    J. Grande,1 R. Leduc,2 The DeKAF Study Group.

  • Cross-Talk Between TLR and BCR Pathways Induces CNI-Resistance in B-Cells Responding to Blood Group A-Antigens: A Novel Paradigm for Treatment with TLR-Inhibitor for CNI-Resistant AMR.

    H. Sakai, Y. Tanaka, H. Ohdan.

  • CTLA4 Negatively Regulates Donor-Reactive CXCR5+PD1+ T Follicular Helper Cell Responses Following Transplantation.

    I. Badell,1 D. Liu,1 S. Suchard,2 S. Nadler,2 M. Ford.1

  • Culture Specific Interventions to Increase Organ Donation Advocacy in a Hispanic Serving Institution.

    Y. Tasnif,1 S. Ghaddar,2 S. Saladin,3 A. Alaniz.1

  • CXCL12 as Innovative Immune Isolating Chemokine for Microencapsulated Allo and Xeno-Transplantation in NHPs.

    M. Sremac,1 A. Saraya,1 O. Clemente,1 M. Penson,1 S. Chavan,3 N. Chronos,3 C. Schuetz,2 J. Lei,2 J. Markmann,2 T. Brauns,1 M. Poznansky.1

  • Cytokine Networks in Kidney Transplant Patients.

    R. Sabat,1 E. Witte,1 P. Reinke,2 K. Wolk,1 N. Babel.3,4

  • Cytokine Storm in Acute Post-Hepatectmy Phase Associates with Liver Injury and Impaired Liver Regeneration.

    Y. Xu,1,2 N. Navarro-Alvarez,1 J. Dong,2 J. Markmann,1 H. Yeh.1

  • Cytomegalovirus Infection After Cardiac Transplantation.

    O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.

  • Cytometric Deep Profiling of the CD8+ T-Cell Compartment in Transplant Patients with CMV Viremia.

    V. Ferreira, D. Kumar, S. Husain, M. Bhat, P. Ashton, A. Humar.

Jump to:  View All • a b [c] d e f g h i j k l m n o p q r s t u v w x y z

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences